Resection of adrenocortical carcinoma liver metastasis: Is it justified?

Annals of Surgical Oncology

Volumn 19, Issue 8, 2012, Pages 2643-2651

  Gaujoux, Sébastien ^a   Al Ahmadie, Hikmat ^a   Allen, Peter J ^a   Gonen, Mithat ^a   Shia, Jinru ^a   D'Angelica, Michael ^a   Dematteo, Ronald ^a   Fong, Yuman ^a   Blumgart, Leslie ^a   Jarnagin, William R ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; PROTEIN P53;

ADRENAL CORTEX CARCINOMA; ADULT; AMINO ACID SEQUENCE; ARTICLE; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; GENE MUTATION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; LIVER RESECTION; MALE; MORBIDITY; OPERATION DURATION; OVERALL SURVIVAL; POSTOPERATIVE COMPLICATION; PROTEIN EXPRESSION; SURGICAL MORTALITY; TREATMENT OUTCOME; TUMOR LOCALIZATION; TUMOR RECURRENCE; TUMOR VOLUME;

ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL CARCINOMA; ADULT; BETA CATENIN; DNA, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HEPATECTOMY; HUMANS; IMMUNOENZYME TECHNIQUES; LIVER NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; WNT PROTEINS;

EID: 84865024540     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-012-2358-7     Document Type: Article

References (50)

1. SH Golden KA Robinson I Saldanha, et al. 2009 Clinical review: Prevalence and incidence of endocrine and metabolic disorders in the United States: a comprehensive review J Clin Endocrinol Metab. 94 6 1853 1878 19494161 10.1210/jc.2008-2291 1:CAS:528:DC%2BD1MXntFGmsL0%3D
2. M Fassnacht S Johanssen M Quinkler, et al. 2009 Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a revised TNM classification Cancer. 115 2 243 250 19025987 10.1002/cncr.24030
3. KY Bilimoria WT Shen D Elaraj, et al. 2008 Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors Cancer. 113 11 3130 3136 18973179 10.1002/cncr.23886
4. E Kebebew E Reiff QY Duh, et al. 2006 Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress? World J Surg. 30 5 872 878 16680602 10.1007/s00268-005-0329-x
5. Abiven G, Coste J, Groussin L, et al. Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients. J Clin Endocrinol Metab. 2006.
6. P Icard P Goudet C Charpenay, et al. 2001 Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons Study Group World J Surg. 25 7 891 897 11572030 10.1007/s00268-001-0047-y 1:STN:280:DC%2BD3MrisVGisg%3D%3D
7. G Assie G Antoni F Tissier, et al. 2007 Prognostic parameters of metastatic adrenocortical carcinoma J Clin Endocrinol Metab. 92 1 148 154 17062775 10.1210/jc.2006-0706 1:CAS:528:DC%2BD2sXpsVKjtQ%3D%3D
8. RD Schulick MF Brennan 1999 Long-term survival after complete resection and repeat resection in patients with adrenocortical carcinoma Ann Surg Oncol. 6 8 719 726 10622498 10.1007/s10434-999-0719-7 1:STN:280:DC%2BD3c%2Fos1aisg%3D%3D
9. R Bellantone A Ferrante M Boscherini, et al. 1997 Role of reoperation in recurrence of adrenal cortical carcinoma: results from 188 cases collected in the Italian National Registry for Adrenal Cortical Carcinoma Surgery. 122 6 1212 1218 9426440 10.1016/S0039-6060(97)90229-4 1:STN:280:DyaK1c%2Foslyhsg%3D%3D
10. B Ragazzon G Assie J Bertherat 2011 Transcriptome analysis of adrenocortical cancers: from molecular classification to the identification of new treatments Endocr Relat Cancer. 18 2 R15 R27 21208995 1:CAS:528: DC%2BC3MXmvVajtL8%3D
11. S Gaujoux S Grabar M Fassnacht, et al. 2011 beta-catenin activation is associated with specific clinical and pathologic characteristics and a poor outcome in adrenocortical carcinoma Clin Cancer Res. 17 2 328 336 21088256 10.1158/1078-0432.CCR-10-2006 1:CAS:528:DC%2BC3MXmslyqsA%3D%3D
12. B Ragazzon R Libe S Gaujoux, et al. 2010 Transcriptome analysis reveals that p53 and {beta}-catenin alterations occur in a group of aggressive adrenocortical cancers Cancer Res. 70 21 8276 8281 20959480 10.1158/0008-5472. CAN-10-2014 1:CAS:528:DC%2BC3cXhtlKjtrjF
13. C Gicquel X Bertagna H Schneid, et al. 1994 Rearrangements at the 11p15 locus and overexpression of insulin-like growth factor-II gene in sporadic adrenocortical tumors J Clin Endocrinol Metab. 78 6 1444 1453 7911125 10.1210/jc.78.6.1444 1:STN:280:DyaK2c3lvFOlsQ%3D%3D
14. R Libe L Groussin F Tissier, et al. 2007 Somatic TP53 mutations are relatively rare among adrenocortical cancers with the frequent 17p13 loss of heterozygosity Clin Cancer Res. 13 3 844 850 17289876 10.1158/1078-0432.CCR-06- 2085 1:CAS:528:DC%2BD2sXhsVyrs70%3D
15. JL Westra M Schaapveld H Hollema, et al. 2005 Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients J Clin Oncol. 23 24 5635 5643 16110022 10.1200/JCO.2005.04.096 1:CAS:528:DC%2BD2MXhtVersrzN
16. G Lughezzani M Sun P Perrotte, et al. 2010 The European Network for the Study of Adrenal Tumors staging system is prognostically superior to the international union against cancer-staging system: a North American validation Eur J Cancer. 46 4 713 719 20044246 10.1016/j.ejca.2009.12.007
17. A Stojadinovic RA Ghossein A Hoos, et al. 2002 Adrenocortical carcinoma: clinical, morphologic, and molecular characterization J Clin Oncol. 20 4 941 950 11844815 10.1200/JCO.20.4.941 1:CAS:528:DC%2BD38XitFOqtbo%3D
18. J Concato P Peduzzi TR Holford, et al. 1995 Importance of events per independent variable in proportional hazards analysis. I. Background, goals, and general strategy J Clin Epidemiol. 48 12 1495 1501 8543963 10.1016/0895- 4356(95)00510-2 1:STN:280:DyaK287js1Wnuw%3D%3D
19. GM Furnival RW Wilson 1974 Regression by leaps and bounds Technometrics. 16 499 511 10.1080/00401706.1974.10489231
20. R Adam L Chiche T Aloia, et al. 2006 Hepatic resection for noncolorectal nonendocrine liver metastases: analysis of 1,452 patients and development of a prognostic model Ann Surg. 244 4 524 535 16998361
21. Lughezzani G, Sun M, Perrotte P, et al. The European Network for the Study of Adrenal Tumors staging system is prognostically superior to the international union against cancer-staging system: a North American validation. Eur J Cancer. 2009.
22. B Allolio M Fassnacht 2006 Clinical review. Adrenocortical carcinoma: clinical update J Clin Endocrinol Metab. 91 6 2027 2037 16551738 10.1210/jc.2005-2639 1:CAS:528:DC%2BD28XlvVCgsr4%3D
23. I Veytsman L Nieman T Fojo 2009 Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinoma J Clin Oncol. 27 27 4619 4629 19667279 10.1200/JCO.2008.17.2775 1:CAS:528:DC%2BD1MXhtlCns7%2FL
24. EG Grubbs GG Callender Y Xing, et al. 2010 Recurrence of adrenal cortical carcinoma following resection: surgery alone can achieve results equal to surgery plus mitotane Ann Surg Oncol. 17 1 263 270 19851811 10.1245/s10434-009- 0716-x
25. J Abraham S Bakke A Rutt, et al. 2002 A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a p-glycoprotein antagonist Cancer. 94 9 2333 2343 12015757 10.1002/cncr.10487 1:CAS:528:DC%2BD38XktF2hs7Y%3D
26. Khan TS, Imam H, Juhlin C, et al. Streptozocin and o,p'DDD in the treatment of adrenocortical cancer patients: long-term survival in its adjuvant use. Ann Oncol. 2000;11(10):1281-7.
27. SK Williamson D Lew GJ Miller, et al. 2000 Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma: a Southwest Oncology Group study Cancer. 88 5 1159 1165 10699907 10.1002/(SICI)1097- 0142(20000301)88:5<1159::AID-CNCR28>3.0.CO;2-R 1:CAS:528: DC%2BD3cXhvFGhsLo%3D
28. BJ Wood J Abraham JL Hvizda, et al. 2003 Radiofrequency ablation of adrenal tumors and adrenocortical carcinoma metastases Cancer. 97 3 554 560 12548596 10.1002/cncr.11084
29. J Bauditz M Quinkler W Wermke 2009 Radiofrequency thermal ablation of hepatic metastases of adrenocortical cancer-a case report and review of the literature Exp Clin Endocrinol Diabetes. 117 7 316 319 19053031 10.1055/s-0028-1087178 1:CAS:528:DC%2BD1MXhtVeltLbL
30. T de Baere J Palussiere A Auperin, et al. 2006 Midterm local efficacy and survival after radiofrequency ablation of lung tumors with minimum follow-up of 1 year: prospective evaluation Radiology. 240 2 587 596 16864679 10.1148/radiol.2402050807
31. J Abraham T Fojo BJ Wood 2000 Radiofrequency ablation of metastatic lesions in adrenocortical cancer Ann Intern Med. 133 4 312 313 10929185 1:STN:280:DC%2BD3czpvF2ksg%3D%3D
32. RT Ripley CD Kemp JL Davis, et al. 2011 Liver resection and ablation for metastatic adrenocortical carcinoma Ann Surg Oncol. 18 7 1972 1979 21301973 10.1245/s10434-011-1564-z
33. J Cazejust T De Baere A Auperin, et al. 2010 Transcatheter arterial chemoembolization for liver metastases in patients with adrenocortical carcinoma J Vasc Interv Radiol. 21 10 1527 1532 20801688 10.1016/j.jvir.2010.05.020
34. I Di Carlo A Toro F Sparatore, et al. 2006 Liver resection for hepatic metastases from adrenocortical carcinoma HPB (Oxford). 8 2 106 109 10.1080/13651820500471848
35. J Weitz LH Blumgart Y Fong, et al. 2005 Partial hepatectomy for metastases from noncolorectal, nonneuroendocrine carcinoma Ann Surg. 241 2 269 276 15650637 10.1097/01.sla.0000150244.72285.ad
36. DE Schteingart GM Doherty PG Gauger, et al. 2005 Management of patients with adrenal cancer: recommendations of an international consensus conference Endocr Relat Cancer. 12 3 667 680 16172199 10.1677/erc.1.01029 1:STN:280:DC%2BD2MrgtVWqsg%3D%3D
37. A Berruti M Terzolo P Sperone, et al. 2005 Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial Endocr Relat Cancer. 12 3 657 666 16172198 10.1677/erc.1.01025 1:CAS:528:DC%2BD2MXht1SjsrrN
38. P Icard A Louvel Y Chapuis 1992 Survival rates and prognostic factors in adrenocortical carcinoma World J Surg. 16 4 753 758 1413845 10.1007/BF02067377 1:STN:280:DyaK3s%2FjtlGgtw%3D%3D
39. F Crucitti R Bellantone A Ferrante, et al. 1996 The Italian Registry for Adrenal Cortical Carcinoma: analysis of a multi-institutional series of 129 patients. The ACC Italian Registry Study Group Surgery. 119 2 161 170 8571201 10.1016/S0039-6060(96)80164-4 1:STN:280:DyaK287msFCltg%3D%3D
40. R Adam T Aloia J Krissat, et al. 2006 Is liver resection justified for patients with hepatic metastases from breast cancer? Ann Surg. 244 6 897 908 17122615 10.1097/01.sla.0000246847.02058.1b
41. R Adam G Pascal D Castaing, et al. 2004 Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases? Ann Surg. 240 6 1052 1061 15570210 10.1097/01.sla.0000145964.08365. 01 discussion 1061-4
42. RJ Gonzalez EP Tamm C Ng, et al. 2007 Response to mitotane predicts outcome in patients with recurrent adrenal cortical carcinoma Surgery. 142 6 867 874 18063070 10.1016/j.surg.2007.09.006
43. Berruti A, Fassnacht M, Baudin E, et al. Adjuvant therapy in patients with adrenocortical carcinoma: a position of an international panel. J Clin Oncol. 2010;28(23):e401-2; author reply e403.
44. M Terzolo A Angeli M Fassnacht, et al. 2007 Adjuvant mitotane treatment for adrenocortical carcinoma N Engl J Med. 356 23 2372 2380 17554118 10.1056/NEJMoa063360 1:CAS:528:DC%2BD2sXmt1WnsLg%3D
45. LS Kirschner 2006 Emerging treatment strategies for adrenocortical carcinoma: a new hope J Clin Endocrinol Metab. 91 1 14 21 16234301 10.1210/jc.2005-1739 1:CAS:528:DC%2BD28Xms1aitw%3D%3D
46. M Doghman J Cazareth E Lalli 2008 The T cell factor/beta-catenin antagonist PKF115-584 inhibits proliferation of adrenocortical carcinoma cells J Clin Endocrinol Metab. 93 8 3222 3225 18544621 10.1210/jc.2008-0247 1:CAS:528:DC%2BD1cXpvVOlsLs%3D
47. JR Prosperi KH Goss 2010 A Wnt-ow of opportunity: targeting the Wnt/beta-catenin pathway in breast cancer Curr Drug Targets. 11 9 1074 1088 20545611 10.2174/138945010792006780 1:CAS:528:DC%2BC3cXhtFeqsr3J
48. S Gaujoux F Tissier L Groussin, et al. 2008 Wnt/beta-catenin and 3′,5′-cyclic adenosine 5′-monophosphate/protein kinase A signaling pathways alterations and somatic beta-catenin gene mutations in the progression of adrenocortical tumors J Clin Endocrinol Metab. 93 10 4135 4140 18647815 10.1210/jc.2008-0631 1:CAS:528:DC%2BD1cXht1GmurjM
49. Ragazzon B, Libe R, Gaujoux S, et al. Transcriptome analysis reveals that p53 and {beta}-catenin alterations occur in a group of aggressive adrenocortical cancers. Cancer Res. 2010.
50. AM McNicol CE Nolan AJ Struthers, et al. 1997 Expression of p53 in adrenocortical tumours: clinicopathological correlations J Pathol. 181 2 146 152 9120717 10.1002/(SICI)1096-9896(199702)181:2<146::AID-PATH744>3.0.CO;2-7 1:STN:280:DyaK2s3ks12iuw%3D%3D